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Protein modification by the ubiquitin-like protein ISG15 is an
interferon (IFN) effector system, which plays a major role in antiviral
defense. ISG15 modification is counteracted by the isopeptidase
USP18, a major negative regulator of IFN signaling, which was also
shown to exert its regulatory function in an isopeptidase-indepen-
dent manner. To dissect enzymatic and nonenzymatic functions of
USP18 in vivo, we generated knock-in mice (USP18C61A/C61A) express-
ing enzymatically inactive USP18. USP18C61A/C61A mice displayed in-
creased levels of ISG15 conjugates, validating that USP18 is a major
ISG15 isopeptidase in vivo. Unlike USP18−/− mice, USP18C61A/C61A
animals did not exhibit morphological abnormalities, fatal IFN hy-
persensitivity, or increased lethality, clearly showing that major
USP18 functions are unrelated to its protease activity. Strikingly,
elevated ISGylation in USP18C61A/C61A mice was accompanied
by increased viral resistance against vaccinia virus and influenza B
virus infections. Enhanced resistance upon influenza B infection in
USP18C61A/C61A mice was completely reversed in USP18C61A/C61A mice,
which additionally lack ISG15, providing evidence that the observed
reduction in viral titers is ISG15 dependent. These results suggest
that increasing ISGylation by specific inhibition of USP18 protease
activity could constitute a promising antiviral strategy with only
a minimal risk of severe adverse effects.
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Protein modification by the ubiquitin-like (UBL) modifier in-terferon (IFN)-stimulated gene 15 (ISG15) is strongly induced
by type I IFNs and represents one of the major antiviral IFN ef-
fector systems (1). ISG15 has weak sequence identity to ubiquitin
and is structurally characterized by two ubiquitin-like domains
connected by a short linker region (2). In analogy to ubiquitin,
ISG15 is covalently conjugated to protein targets via the consecutive
action of an E1-activating enzyme (Ube1L) (3), an E2-conjugating
enzyme (UbcH8) (4), and a few E3 ligases. All enzymes involved in
the conjugation process are themselves strongly inducible by type I
IFNs. The major E3 ligases for human and murine ISG15 modifi-
cation (ISGylation) are hHERC5 (5, 6) and mHERC6 (7, 8), re-
spectively. hHERC5 is associated with polyribosomes and newly
synthesized proteins are modified by ISG15 in a cotranslational
manner (9). Thus, it was suggested that ISG15 modification of virus-
derived proteins, which are the most prevalent translational prod-
ucts in a virus-infected cell, mediates the antiviral activity of the
ISGylation system. In line with this suggestion, ISG15 modification
of the human papilloma virus protein HPV16 L1 interfered with
virus assembly and decreased the infectivity of HPV in a dominant
manner (9). Moreover, ISGylation of the influenza virus protein
NS1A prevents interaction with importin-α and thereby interferes
with the capability of NS1A to counteract host defense (10). ISG15
is also conjugated to cellular proteins. For example, ISGylation
increases the stability of the IFN regulatory factor 3 (IRF3),
resulting in enhanced activation of IRF3 target genes (11, 12).
Consistent with the antiviral function, mice lacking ISG15 are
more susceptible to influenza A and B, Sindbis, and herpes virus
infections (13). However, antiviral responses against vesicular
stomatitis virus (VSV) and lymphocytic choriomeningitis virus
(LCMV) are not altered (14). For both influenza B and Sindbis
virus infection, the antiviral function of ISG15 is dependent on its
ability to form conjugates because mice lacking the ISG15 E1
enzyme, UbE1L, are also susceptible to these infections (15, 16).
Several viruses including influenza B virus, vaccinia virus (VACV),
and Crimean Congo hemorrhagic fever virus (CCHFV) have
evolved strategies to target ISG15 conjugation, further suggesting
an important antiviral role of ISGylation (3, 17–19).
Conjugation of ISG15 to its substrates is counteracted by the
activity of ubiquitin-specific protease 18 (USP18/UBP43) (20).
In vitro studies also provided evidence for other USPs to be
cross-reactive for ISG15, but the relevance of these isopeptidases
for deISGylation in vivo is unclear (21). Beyond enhanced
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ISGylation, USP18 knockout (USP18−/−) mice develop severe brain
malformations and have a shortened lifespan (22). In addition,
these animals fail to properly terminate IFN-signaling, exhibit
enhanced IFN target gene expression, and show lethal hyper-
sensitivity to poly(I:C) injections (23). Furthermore, IFN de-
sensitization, which assures long-term refractoriness of the IFN
signaling pathway, is abrogated in USP18−/− mice (24), under-
lining the role of USP18 as a critical negative regulator of the
IFN pathway. USP18−/− mice also exhibit increased resistance to
intracranial (i.c.) infections with VSV and LCMV (25). The
phenotypic alterations seen in USP18−/− mice were first exclu-
sively ascribed to enhanced ISG15 modification. However, sub-
sequent analysis of mice doubly deficient for either USP18 and
ISG15 (26) or USP18 and Ube1L (27) surprisingly revealed that
the lack of ISGylation cannot rescue the brain injuries and is not
able to overcome the lethality induced by poly(I:C) in USP18−/−
mice. Furthermore, irrespective of its protease activity, USP18
was shown to compete with JAK1 for binding to the IFNAR2,
thereby negatively regulating the type I IFN response (28) in an
isopeptidase-independent manner.
To differentiate between enzymatic and nonenzymatic physi-
ological functions of USP18 and to study the consequences of
selective inhibition of USP18 protease activity in vivo, we have
now generated and characterized knock-in mice expressing mu-
tant USP18 protein selectively lacking the isopeptidase activity.
Results
Generation of Mice Expressing Catalytically Inactive USP18 Protein. In
murine USP18 the cysteine at position 61 (Cys61) was reported to
be essential for protease activity (20). To validate that mutation of
Cys61 inactivates the isopeptidase activity, USP18 carrying an
N-terminal S-peptide epitope tag (S-USP18) and mutants thereof
were expressed in HEK293T cells. In particular the codons of
USP18 for either Cys61 (C61A), Cys62 (C62A), or both (C61A/
C62A) were replaced by those encoding for alanine. Subsequently,
protein extracts of transfected cells were analyzed for the ISG15-
specific reactivity of USP18 and its derivatives using ISG15-
vinylsulfone (ISG15-VS). ISG15-VS acts as an active site-directed
probe and irreversibly reacts with the catalytic core of ISG15
proteases. ISG15-VS was readily linked to WT USP18 and
USP18C62A but neither USP18C61A nor USP18C61A/C62A did react
with ISG15-VS (Fig. S1A), showing that Cys61 is essential for the
protease activity of USP18. To generate mice that express cat-
alytically inactive USP18C61A, a knock-in targeting strategy was
applied (Fig. S1B). Via homologous recombination, the codon
for the active site cysteine (C61) was replaced by a codon specific
for alanine (C61A). Positive ES cell clones were identified and used
to generate germ-line chimeras and heterozygous animals were
mated to yield homozygous mice (USP18C61A/C61A). Success-
ful mutation was validated by Southern blot analysis (Fig. S1C).
cDNA sequencing proved that USP18C61A/C61A animals ex-
press a mutant USP18C61A transcript (Fig. S1D). To confirm that
targeted mutagenesis of the USP18 gene locus did not alter regula-
tory properties, bone-marrow–derived macrophages (BMMs) were
isolated and stimulated with IFN-β. Western blot analysis
showed that the induction kinetics and protein levels of
USP18C61A protein were similar to that observed in WT cells
(Fig. S1E). USP18C61A/C61A animals were born according to
Mendelian ratios and in contrast to USP18−/− mice, did not exhibit
macroscopic alterations, reduced life expectancy, or brain abnor-
malities. Even no abnormalities were detected in USP18C61A/C61A
mice backcrossed to C57BL/6, a genetic background, in which
USP18 deficiency causes embryonic lethality accompanied by
malformation and growth retardation around embryonic day 15.5
(E15.5) (Fig. S2). Thus, we established a mouse strain in which the
endogenous USP18 gene was mutated to express a USP18 protein
selectively lacking its isopeptidase activity.
USP18C61A/C61A Mice Demonstrate Increased ISGylation. In addi-
tion to functioning as a deconjugating enzyme for ISG15, it has
been shown in cells that USP18 can regulate IFN signaling in
a protease-independent manner (28). Thus, the enhanced
ISGylation seen in the USP18-deficient mice could have been due
to either the enhanced IFN signaling or impaired deISGylation. In
addition, previous in vitro studies have provided evidence for other
USPs that exhibit cross-reactivity to ISG15 (21, 29). Therefore, we
evaluated whether the loss of USP18 isopeptidase activity is suffi-
cient to augment ISG15 modification in vivo. USP18C61A/C61A or
WT mice were stimulated with poly(I:C), and ISG15-conjugated
proteins were monitored in lysates from liver, lung, lymph nodes,
spleen, and thymus (Fig. 1A and Fig. S3A). In addition, ISG15
modification was analyzed in BMMs treated with IFN-α, IFN-β,
poly(I:C), or LPS (Fig. 1B and Fig. S3B). Inactivation of the USP18
isopeptidase activity significantly increased levels of ISGylated
substrates upon IFN-β, poly(I:C), or LPS stimulation and in all
assayed tissues and cell types, indicating that USP18 isopeptidase
function is necessary to counteract ISGylation of multiple proteins.
Remarkably, lungs from USP18C61A/C61A mice also displayed sig-
nificantly enhanced levels of unconjugated ISG15. We also followed
the kinetics of ISGylation over several days (Fig. 1C and Fig. S3C).
Both in WT and in USP18C61A/C61A mice, the levels of ISG15-
conjugated proteins reached a maximum in liver lysates 24 h after
induction with poly(I:C). Levels of ISG15-modified substrates
in USP18C61A/C61A mice compared with WT controls were sig-
nificantly elevated on days 1, 2, 3, and 4 after induction. However,
on days 3 and 4 after induction, levels of ISGylation decreased
in both genotypes, suggesting that either other isopeptidases de-
conjugate ISG15 or that ISGylated substrates are removed by
physiologic turnover. In contrast, overall ubiquitin modification
did not differ between WT and USP18C61A/C61A murine embry-
onic fibroblasts (MEFs) (Fig. S4A). Together, these results clearly
show that selective inactivation of the USP18 isopeptidase activity
causes increased and prolonged ISGylation, which appears to be
only partially compensated by other isopeptidases in vivo, if at all.
USP18 Protease Activity Is Not Critical for IFN Induction, Signaling, or
Desensitization. Several reports suggested a role of ISG15 and
USP18 in the regulation of the type I IFN response. The im-
portance of USP18-mediated regulation is most strikingly shown
by the fact that the lack of USP18 results in lethal hypersensi-
tivity upon poly(I:C) injection (23, 26). To evaluate the contri-
bution of the USP18 protease function in poly(I:C)-induced
hypersensitivity, USP18C61A/C61A mice were challenged with this
IFN-inducing TLR3 agonist. In contrast to USP18−/− mice, in
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Fig. 1. Inactivation of USP18 isopeptidase enhances ISGylation. (A)
USP18C61A/C61A mice (C61A) showed enhanced ISGylation in different organs.
Mice were injected with poly(I:C) and 24 h later protein lysates were ana-
lyzed by immunoblotting. (B) USP18C61A/C61A BMMs displayed enhanced
ISGylation levels after treatment with 250 units/mL IFN-α, 250 units/mL IFN-β,
25 μg/mL poly(I:C) [p(I:C)] or 100 ng/mL LPS for 24 h. (C) Time course of
ISGylation in liver lysates. WT and USP18C61A/C61A animals were treated i.p.
once with 5 μg/g bodyweight poly(I:C) and ISGylation was analyzed 1–4 d
after injection. Western blots are representative of three to five indepen-
dent experiments (densitrometric analysis is depicted in Fig. S3).
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which 100% of the mice succumbed to poly(I:C)-induced lethality
within 1 d, neither USP18C61A/C61A nor WT mice died (Fig. 2A),
showing that the protease activity of USP18 is not essential to
counteract the proinflammatory response upon poly(I:C) admin-
istration. TLR3 stimulation activates a signaling cascade, which
culminates in the activation of IRF3 and induces expression of
type I IFNs (30). Furthermore, ISG15 was reported to be conju-
gated to IRF3, thereby increasing its stability (11, 12). Thus, we
evaluated stability and phosphorylation of IRF3 and type I IFN
induction upon poly(I:C) stimulation in USP18C61A/C61A cells and
mice. Neither the total contents of IRF3 nor the kinetics or
the intensities of IRF3 phosphorylation differed between cells of
both genotypes (Fig. 2B). Concordantly, IFN-β serum levels in
USP18C61A/C61A mice treated with poly(I:C) were not affected
(Fig. 2C). These results strongly indicate that the enzymatic ac-
tivity of USP18 is dispensable for normal poly(I:C)-mediated IFN
induction and that its loss does not affect IRF3 stability or acti-
vation. USP18-deficient fibroblasts also did not exhibit alterations
in the kinetic of IRF3 phosphorylation (Fig. S4B). To analyze the
potential role of USP18 isopeptidase activity in IFN signaling,
STAT1 phosphorylation after IFN-β stimulation was monitored in
MEFs and BMMs. As reported previously (23), STAT1 phos-
phorylation was prolonged in USP18-deficient MEFs (Fig. 2D).
In contrast, kinetics and intensity of STAT1 phosphorylation did
not differ between WT and USP18C61A/C61A MEFs (Fig. 2D).
Similarly, no differences were detected between WT and
USP18C61A/C61A BMMs (Fig. 2E). In addition, Northern blot
analysis showed that expression of the type I IFN target genes
IRF1 and IRF7 was not altered in USP18C61A/C61A cells (Fig. 2F).
IFN-α stimulation can cause a state of refractoriness (desensi-
tization) in which a second stimulus can no longer induce IFN
signaling. Lack of USP18 was shown to abrogate this desensitizing
effect of IFN-α in vivo (24), whereas USP18 expression was suf-
ficient to establish this state of refractoriness (31). To monitor
IFN-mediated desensitization in vivo, animals were first injected
with IFN-α, which induces STAT1 phosphorylation after 1 h.
Subsequently, mice received a second IFN-α injection 8 h later
and P-STAT1 was analyzed 1 h after the second treatment. The
initial injection of IFN-α induced P-STAT1 in liver protein lysates
of WT and USP18C61A/C61A mutant mice, whereas the second
injection failed to activate STAT1 in both genotypes (Fig. 2G).
Thus, desensitization was observed in WT and USP18C61A/C61A
animals, indicating that the enzymatic activity of USP18 is dis-
pensable for this effect. Collectively, these data show that in vivo
type I IFN induction and signaling is not influenced by the loss of
USP18 isopeptidase activity, strongly suggesting that regulatory
properties of USP18 within this context are exerted in a non-
enzymatic manner.
Enhanced Resistance of USP18C61A/C61A MEFs to the Cytopathic Effect
of VSV Infection. As ISGylation represents one of the major type I
IFN effector systems, the role of USP18 enzymatic activity was
assessed in viral infection models. USP18−/− mice were reported
to be resistant to both i.c. VSV and LCMV infection (25). When
WT and USP18C61A/C61A MEFs were challenged with VSV, we
found that USP18C61A/C61A cells were about 100-fold more re-
sistant against the cytopathic effect of VSV than WT cells. The
same effect was seen upon prestimulation with IFN-β (Fig. 3A).
This was accompanied by a dramatic increase in ISGylation in
USP18C61A/C61A cells (Fig. 3B). However, the pronounced
cytoprotective effect in cell culture was not mirrored by altered
survival rates of USP18C61A/C61A mice upon intracranial (i.c.)
(Fig. S5A) or i.v. infection with VSV (Fig. S5B). Also during
infection with the noncytopathic LCMV, the survival kinetics did
not differ between USP18C61A/C61A mice and WT controls upon
i.c. infection (Fig. S5C). These results show a correlation be-
tween enhanced ISGylation and viral resistance upon VSV in-
fection in cell culture, which does not translate into enhanced
survival in vivo.
Inactivation of USP18 Protease Activity Increases Resistance to VACV
Infections. ISG15 plays an important role in the host response to
VACV infection and the viral E3 protein functions as an immune
evasion protein to inhibit ISG15 conjugation (17, 19). Thus, we
characterized the role of USP18 isopeptidase activity in VACV
infection. USP18C61A/C61A MEFs were protected against the
cytopathic effects of VACV infection, whereas WT cells were
highly susceptible (Fig. 4A). This effect was accompanied by
significantly lower virus titers in cultures of USP18C61A/C61A cells
in comparison with WT controls (Fig. 4B). IRF3 phosphorylation
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after infection was unaltered between WT and USP18C61A/C61A
MEFs (Fig. S6). USP18C61A/C61A BMMs showed lower levels of
VACV E3 protein, coinciding with enhanced ISGylation (Fig.
4C). As VACV E3 was previously shown to counteract the host
defense, we asked whether E3 might be ISGylated in cells
lacking USP18 isopeptidase activity. However, neither endoge-
nous E3 nor E3 overexpressed in USP18C61A/C61A cells could be
shown to be modified by ISG15 (Fig. S7).
Upon infection of USP18C61A/C61A mice with VACV, sig-
nificantly reduced viral titers were detected in the lung (Fig.
4D) and spleen (Fig. 4E). Most strikingly, after infection with 105
pfu per mouse, all USP18C61A/C61A mice survived the infection,
whereas 7 of 10 WT animals died between days 7 and 9 (Fig. 4F).
Altogether, inactivation of the USP18 isopeptidase activity
increases resistance to VACV both in cell culture and in mice.
Inactivation of USP18 Protease Activity Increases Resistance to Influenza
B Virus Infections. Previous studies have demonstrated a critical role
for ISGylation in the control of influenza B virus infection (15). To
evaluate, if increasing the levels of ISGylation by USP18 protease
inactivation can boost antiviral activity, USP18C61A/C61A mice were
infected with influenza B/Yamagata/88 virus. As WT mice do not
develop severe disease symptoms following influenza B virus in-
fection, we evaluated viral loads within the lungs of mice to assess
resistance to infection. As previously reported (13) viral titers were
increased nearly 1000-fold in ISG15−/− animals (Fig. 5A). In-
terestingly, in the infected USP18C61A/C61A mice, we observed a
sevenfold decrease in viral loads at 3 d postinfection compared
with WT mice (Fig. 5A). Because USP18 has been previously
shown to regulate IFN signaling independent of its ISG15 decon-
jugating activity we wanted to determine if the resistance that
we observed in the USP18C61A/C61A-infected mice was dependent
on ISG15. ISG15−/− mice were bred onto the USP18C61A/C61A
background and viral loads were analyzed in these ISG15−/−
USP18C61A/C61A mice following influenza B virus infection.
When ISG15 was eliminated from USP18C61A/C61A mice, viral
titers were similar to those observed in ISG15−/− mice (Fig. 5A),
providing strong evidence that the loss of ISG15 deconjugation
causes increased resistance against influenza B virus infection. To
determine whether ISGylation directly affects influenza B virus
replication, we next evaluated viral replication in primary mouse
tracheal epithelial cells (mTECs). mTECs derived from WT,
ISG15−/−, USP18C61A/C61A, or ISG15−/−USP18C61A/C61A mice were
either left untreated or were pretreated with IFN-β and then
infected with influenza B virus. In mTECs not pretreated with
IFN, we detected only minimal differences in viral growth between
the three genotypes (Fig. 5B). Following pretreatment with IFN,
we observed a significant decrease in viral growth in the
USP18C61A/C61A cells with viral replication being reduced by about
7-fold after 72 h postinfection, whereas mTECs derived from
ISG15−/−mice exhibited a 33-fold increase in viral titers compared
with WT controls (Fig. 5 C and D). Once again the reduced rep-
lication observed in the USP18C61A/C61A mTECs was dependent
on ISG15 because mTECs derived from ISG15−/−USP18C61A/C61A
mice exhibited increased replication similar to that observed in the
ISG15−/− mTECs (Fig. 5 C and D). ISG15 protein expression
analysis from IFN-stimulated mTECs confirmed that in both WT
and USP18C61A/C61A mTECs, ISG15 and ISG15 conjugates were
induced, with an increase in the levels of ISG15 conjugates being
observed in the USP18C61A/C61A cells (Fig. 5E and Fig. S8). In-
terestingly, whereas the amount of ISG15 conjugates was increased
in the USP18C61A/C61A mTECs, we also observed an increase in the
levels of total ISG15 protein in these cells compared with WT cells
(Fig. 5E and Fig. S8). Together these results clearly show that the
selective inactivation of the USP18 protease activity results in
decreased influenza B viral replication both in cells and in vivo.
Discussion
The findings from our study are briefly summarized in a model
depicted in Fig. S9 and answer several questions concerning the
function of USP18 in vivo. First, the given results show that in
general, the molecular function of USP18 as a negative regulator of
IFN signaling in vivo is mediated in an isopeptidase-independent
manner. In contrast to the complete knockout, USP18C61A/C61A
mice did not develop brain injuries, displayed no prolongation of
STAT1 phosphorylation, and were not hypersensitive to the
administration of poly(I:C). Previous experiments provided evi-
dence for a mechanism where the C terminus of USP18 binds
to IFNAR2 and competes with JAK1 for binding (28). In-
terestingly, mice harboring an amino acid exchange of the con-
served leucine 361 at the C terminus in USP18 (USP18Ity9)
exhibit increased STAT1 expression upon IFN-β induction,
suggesting that the C terminus of USP18 is indeed critical for the
negative regulatory role in IFN signaling (32). USP18 together
with USP12 is the smallest member of the USP family and does
not comprise any other prominent domains besides the catalytic
core (33). Therefore, it was surprising that USP18C61A/C61A mice
develop a phenotype so different from the mice lacking
USP18. Recently, also USPL1, a SUMO-deconjugating en-
zyme, was shown to exert the stabilization of Cajal bodies in
an isopeptidase-independent manner (34), suggesting that
nonenzymatic functions of USPs might be more common than
generally assumed. Thus, loss-of-function experiments and
RNAi-based screens inhibiting ubiquitin- and UBL-deconjugat-
ing enzymes (DUBs) need to be cautiously interpreted.
Second, enhanced ISGylation in USP18C61A/C61A mice showed
that USP18, which so far is the only DUB reported to be specific
for ISG15, is a major deconjugating enzyme for ISG15 in vivo. All
components of the ISGylation system (ISG15, Ube1L, UbcH8, and
HERC5/HERC6) are strongly induced by IFN. Therefore, en-
hanced activation of IFN signaling observed in USP18−/− mice
would force ISGylation even if USP18 isopeptidase activity is di-
rected against other proteins or if loss of the protein can be
compensated. We now show increased and prolonged ISGylation
in USP18C61A/C61A mice, where the IFN signaling pathway is not
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Fig. 4. Inactivation of USP18 protease activity enhances antiviral activity upon
VACV infection. (A) WTMEFs or USP18C61A/C61A (C61A) MEFs were infected with
VACV at 0.01 pfu per cell. Cytopathic effect in the cells was examined by phase-
contrast microscopy. (B) VACV titers are diminished in USP18C61A/C61A cells. One-
step virus growth of VACV-infected (0.001 pfu per cell) USP18C61A/C61A or WT
MEFs. Cells were infected and virus yields were determined by plaque assays for
VACV. (C) Enhanced ISGylation and reduced E3 protein levels in USP18C61A/C61A
BMMs upon VACV infection. USP18C61A/C61A orWT BMMs were infected with 0.01
pfu per cell VACV and protein lysates subjected to immunoblotting using the
indicated antibodies. (D and E) USP18C61A/C61A (C61A) animals showed decreased
viral titers at days 1, 3, and 6 postinfection in lung or spleen, respectively.
USP18C61A/C61A or WT mice were infected i.n. with VACV at 105 pfu per mouse.
The extent of infectious particles from WT (black bars) and USP18C61A/C61A (gray
bars) mice were evaluated by plaque assay in BSC-40 cells. Results represent mean
values from samples of four animals per day and groupwith SE ofmean (SEM). (F)
USP18C61A/C61A mice displayed an improved survival after VACV infection in vivo.
USP18C61A/C61A or WT mice were infected i.n. with VACV at 105 pfu per mouse
[Western Reserve (WR) strain]. The survival of each group (n = 10) is indicated.
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altered in general, clearly indicating that USP18 is a major ISG15
isopeptidase in vivo and that other cross-reactive USPs (21) cannot
fully compensate for the loss of USP18 protease function.
However, efficient ISGylation in USP18C61A/C61A mice clearly
shows that processing of the ISG15 precursor protein is exerted
in an USP18-independent manner.
Third, our results suggest that increasing the levels of ISG15
conjugation can be protective against viral infection. Studies using
ISG15−/− or Ube1L−/− mice have clearly shown that ISGylation is
essential for antiviral activity against some viruses (13, 15). Previous
studies in the USP18−/−mice had shown resistance to viral infection
(25). However, it was unclear if this was due to increased ISG15
conjugates or hypersensitive IFN signaling. Furthermore embryonic
lethality of USP18−/− animals on a C57BL/6 background (Fig. S2)
made it impossible to analyze the consequences of viral infection in
this immunologically well-characterized background. The results
from our study provide strong evidence that enhancing the levels of
ISG15 conjugates can protect the host from at least some viral
infections. It is interesting to note that both influenza B virus and
VACV have developed immune evasion strategies to target ISG15
conjugation. In the case of influenza B virus, the NS1 protein can
block the binding of ISG15 to UbE1L (3), and therefore block
conjugate formation, whereas in the case of VACV, the E3 protein
can inhibit ISG15 conjugation (17, 19). In both of these cases, in-
activation of the USP18 protease activity protected the mice from
infection. The increased resistance observed in USP18−/− mice
infected i.c. with either VSV or LCMV is likely due to the enhanced
IFN signaling and not due to the antiviral actions of ISG15. This is
supported by the lack of a phenotype for either virus infection
observed in the ISG15−/−mice and because no protection was noted
when USP18C61A/C61A mice were challenged with VSV or LCMV.
In a recent study, USP18 was reported to specifically suppress the
IFN response in metallophilic macrophages (35). This suppression
permits a limited amplification of VSV, which in turn secures rep-
lication of a critical amount of virus particles necessary to efficiently
promote adaptive immunity. In agreement with this function,
USP18-deficient mice exhibited reduced survival upon i.v. VSV
infection where the adaptive immune response is critical to prevent
lethality. In contrast, USP18−/− mice exhibit increased resistance to
i.c. VSV infections where viral clearance is mainly IFN dependent
(25). As USP18C61A/C61A and WT mice did not differ in survival
upon i.c. or i.v. infection with VSV, it is unlikely that USP18 pro-
tease activity contributes to the reported suppression of the IFN
response in metallophilic macrophages.
There are several potential mechanisms that could mediate the
increased resistance observed in the USP18C61A/C61A mice.
ISGylation can occur in a cotranslational manner and ISG15
modification of viral proteins has been shown to result in improper
viral assembly (9) or interfere with the capability of distinct viral
proteins like E3 from VACV or NS1A from influenza to coun-
teract cellular defense mechanisms (10, 17). As we observed re-
duced levels of VACV E3 upon infection of BMMs, which
correlated with increased levels of overall ISGylation, it was tempting
to speculate that ISG15 modification of E3 in USP18C61A/C61A ani-
mals might account for the observed increase in resistance. However,
we were unable to detect ISGylation of E3 (Fig. S7), even when
overexpressed in USP18C61A/C61A MEFs followed by IFN stimula-
tion, or in HEK293T cells together with expression constructs for
ISG15 and E1-, E2-, and E3-conjugating enzymes (Fig. S7).
Therefore, the reduced E3 protein levels most likely rather mirrors
reduced viral load in USP18C61A/C61A cells than being the cause for
the enhanced resistance of USP18C61A/C61A cells. Thus, the exact
molecular mechanisms leading to enhanced viral resistance still
require further investigation.
It is quite conceivable that the lack of USP18 isopeptidase
activity increases the pool of ISG15-modified viral proteins
thereby enhancing antiviral activity in USP18C61A/C61A mice.
Alternatively, antiviral activities mediated by ISG15-modified
cellular proteins could be enhanced. Although previous studies
have shown that ISGylation of IRF3 enhanced its stability,
resulting in increased IFN and ISG production, neither poly(I:C)
nor VACV infection substantially altered IRF3 phosphorylation
or stability. Future studies will be needed to explore the potential
targets of enhanced ISGylation in this system.
Altogether, our results suggest that small molecule inhibition of
the USP18 protease activity might be an attractive strategy for the
development of antiviral therapies. USP18C61A/C61A mice repre-
sent a well-suited model system to mimic the consequences of such
a therapeutic strategy and represent a valuable tool to study the
physiological consequences of USP18 protease inhibition and
enhanced ISGylation in innate immunity and tumorigenesis.
Whereas the severe phenotype of USP18−/− mice raised con-
cerns about negative consequences of USP18 protease inhibition,
the present study puts former results in perspective. Lack of
USP18 isopeptidase function increases ISGylation and viral re-
sistance without inducing any obvious physical alterations or
symptoms, restoring confidence that USP18 protease inhibition
could be a well-tolerable antiviral therapeutic approach.
Experimental Procedures
Generation of USP18C61A/C61A mice is described in detail in Fig. S1.
Mice. Mice were housed under specific pathogen free conditions and experi-
ments were performed in accordance with good animal practice as defined by
the relevant national, international, and/or local animal welfare bodies, and
with the Royal Decree (RD 1201/2005). All animal work was approved by the
Ethical Committee of Animal Experimentation (CEEA-CNB) of the Centro
Nacional de Biotecnología (CNB-CSIC). Permit 10015. Studies performed at
Washington University were approved by the Animals Studies Committee at
Washington University protocol 20120181. USP18C61A/C61A mice on a 129/C57BL/6
background were used for LCMV, VACV, and VSV infections and poly(I:C) hy-
persensitivity experiments. For influenza B infections, mice were fully back-
crossed to C57BL/6, confirmed by congenic SNP analysis.
Poly(I:C) and IFN-α Injections. Mice were treated with 5 μg/g bodyweight
poly(I:C) (Invivogen) or IFN-α (1,000 units/g bodyweight) (Calbiochem)
intraperitoneally (i.p.).
ELISA. Blood serum samples frommice (n = 5) were treated with poly(I:C) and
analyzed with the IFN-β ELISA kit (PBL InterferonSource).
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Fig. 5. Inactivation of USP18 protease activity enhances resistance to influenza
B infection in vivo and in vitro. (A) Mice were infected with 1.2 × 104 pfu in-
fluenza B/Yamagata/88 virus i.n. Three days later, viral loads in lung were de-
termined. (B–D) mTECs frommice were either left unstimulated (B) or stimulated
with 30 units IFN-β/mL for 24 h (C) before infection with 9.0 × 105 pfu of in-
fluenza B/Yamagata/88. Viral titers were determined by plaque assays. Growth
curves were determined from two infections, three replicates per experiment. #,
USP18C61A/C61A (C61A) vs. WT P < 0.05; *, ISG15−/− vs. WT P < 0.05. (D) Viral titers
in IFN-β stimulated cultures at 48 h postinfection. **P < 0.005. (E) mTECs were
stimulated with 30 units/mL IFN-β for 24 h. ISG15 and β-actin protein levels were
assessed by Western blot analysis (densitrometric analysis in Fig. S5).
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Isolation of Primary Cells and Cell Culture. MEFs and BMMs were isolated,
cultured (26), and stimulated with IFN-α (Calbiochem), IFN-β (PBL Interferon-
Source), LPS (Sigma), and poly(I:C) (high molecular weight) (Invivogen).
Northern, Southern, and Western Blots. Northern and Southern blots were
performed as described (14). For Western blotting, cells and organs were
lysed in radioimmunoprecipitation assay buffer. Antibodies used are as fol-
lows: P-STAT1 (Tyr701), STAT1, IRF3, phospho-IRF3 (Cell Signaling), USP18
(rabbit antiserum), ISG15 (14), β-actin (I-19, Santa Cruz), and S-Tag (Novagen).
Protein expression in mTECs was analyzed using anti-ISG15 antiserum (15) and
anti–β-actin (Sigma AC-74).
ISG15-VS Probe Reaction. cDNA of mUSP18 in pTriEx2 plasmid was mutated
with QuikChange (Stratagene), transfected in HEK 293T cells (FuGENE HD),
and lysed after 48 h in 50 mM Tris (pH 7.4), 5 mM MgCl2, 250 mM sucrose,
1 mM DTT (36). Lysates (20 μg) were incubated with 1 μg of HA-ISG15-VS
probe (Boston Biochem) for 1 h at 37 °C.
Murine Tracheal Epithelial Cell Cultures. Primary mTECs were generated from
the tracheas of mice as previously described (37). Viral infections of mice and
mTECs are described in Supporting Information.
Statistical Analysis. Statistical differences were evaluated using the Student’s
t test (GraphPad Prism). Differences were considered to be significant when
*P < 0.05, **P < 0.01, or ***P < 0.001.
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